Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada

References

• Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Weir N, et al. Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium. Chest. 2011;140(1):221–9.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Bois du RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Luppi F, Spagnolo P, Cerri S, Richeldi L. The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012;18(5):428–32.
   PubMed Web of Science ®Google Scholar
• The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med. 2012;366(21):1968–77.
   PubMed Web of Science ®Google Scholar
• Collard HR, Loyd JE, King TE Jr, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: A survey of academic physicians. Respir Med. 2007;101(9):2011–6.
   Google Scholar
• Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med. 2008;102(9):1342–8.
   PubMed Web of Science ®Google Scholar
• Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462–7.
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.
   PubMed Web of Science ®Google Scholar
• Cottin V, Cadranel J, Crestani B, et al. Management of idiopathic pulmonary fibrosis in France: A survey of 1244 pulmonologists. Respir Med. 2014;108:195–202.
   Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093–2101.
   PubMed Web of Science ®Google Scholar
• Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4:445–53.
   PubMed Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash- Chahla R, Leseche G, Fournier M. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126:469–475.
   PubMed Web of Science ®Google Scholar
• Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19:128–130.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69–78.
   PubMed Web of Science ®Google Scholar
• Troy LK, Chapman SA, Lake F, Wilsher ML, Honeysett LB, Macansh S, Corte TJ. Current Australasian practice for diagnosis and management of idiopathic pulmonary fibrosis: Where are we now? Respirology. 2015;20:647–653.
   Google Scholar
• Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015;147(2):423–429.
   PubMed Web of Science ®Google Scholar
• Kalluri M, Richman-Eisenstat J. Early and Integrated Palliative Care to Achieve a Home Death in Idiopathic Pulmonary Fibrosis. J Pain Symptom Manage. 2017; doi:10.1016/j.jpainsymman.2016.12.344
   Google Scholar
• Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Review. 2014;23:225–230.
   PubMedGoogle Scholar
• Cottin V, Bergot E, Bourdin A, et al. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Res. 2015;1:00032‐2015.
   Google Scholar
• Flaherty KR, Andrei A-C, King TE, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007;175:1054–1060.
   PubMed Web of Science ®Google Scholar
• Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842–7.
   PubMed Web of Science ®Google Scholar
• McMahon SR, Iwamoto M, Massoudi MS, et al. Comparison of e-mail, fax, and postal surveys of pediatricians. Pediatrics. 2003;111:e299–303.
   PubMed Web of Science ®Google Scholar
• VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007;30(4):303–21.
   PubMed Web of Science ®Google Scholar
• Thorpe C, Ryan B, McLean SL, et al. How to obtain excellent response rates when surveying physicians. Fam Pract. 2009;26(1):65–8.
   PubMed Web of Science ®Google Scholar